Journal profile · ONCOLOGY
Journal of Cancer Research and Therapeutics
ISSN 0973-1482 · eISSN 1998-4138 · Wolters Kluwer Medknow Publications · INDIA · Quarterly
Journal of Cancer Research and Therapeutics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.3; JCR Q4 (journal website); fully open access; median 165 days to acceptance (81 articles, last 24 months); community-reported acceptance: about 95%; 237 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Cancer Research and Therapeutics is published by Wolters Kluwer Medknow Publications and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Head and Neck Cancer Studies, Advanced Radiotherapy Techniques and Hepatocellular Carcinoma Treatment and Prognosis, together about 25.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
The journal will cover technical and clinical studies related to health, ethical and social issues in field of Medical oncology, radiation oncology, medical imaging, radiation protection, non-ionising radiation, radiobiology. Articles with clinical interest and implications will be given preference.
Source: LetPub
Research area (LetPub): ONCOLOGY
Editor-in-chief Daya Nand SharmaPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Head and Neck Cancer StudiesMedicine9.6%
- Advanced Radiotherapy TechniquesPhysics and Astronomy9.4%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine6.1%
- Sarcoma Diagnosis and TreatmentMedicine5.7%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.1%
- Lung Cancer Diagnosis and TreatmentMedicine4.7%
- Endometrial and Cervical Cancer TreatmentsMedicine4.2%
- Lung Cancer Treatments and MutationsMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q4 · ONCOLOGY · rank 287/333
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.3LetPub ·
- Impact factor (publisher)
- 1.4Publisher website ·
- CiteScore 2026-06
- 2.3LetPub ·
- SJR 2026-06
- 0.43LetPub ·
- SNIP 2026-06
- 0.55LetPub ·
- h-index
- 30LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 1,800OpenAlex ·
- 2-year mean citedness
- 1.53OpenAlex ·
- Self-citation rate
- 14.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 222LetPub ·
Articles by year OpenAlex count · 5,600 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 91 | 91 | 10 |
| 2025 | 237 | 237 | 222 |
| 2024 | 247 | 247 | 650 |
| 2023 | 525 | 525 | 1,928 |
| 2022 | 474 | 474 | 2,298 |
| 2021 | 288 | 288 | 1,946 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
165 daysMedian, submission to acceptance · P25–P75 103 days – 262 days
- Acceptance to online
- median 108 days (81 articles)
- Submission to online
- median 279 days
- Sample
- 81 articles with submission and acceptance dates (382 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 monthsLetPub ·
- Average acceptance (community reports)
- 95%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wolters Kluwer Medknow Publications
- Country or region
- INDIA
- Language
- English
- Frequency
- Quarterly
- ISSN
- 0973-1482
- Electronic ISSN
- 1998-4138
- Latest issue on the website
- Volume 22, Issue 2 (May 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Journal of Cancer Research and Therapeutics
What CAS zone is Journal of Cancer Research and Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Cancer Research and Therapeutics is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Cancer Research and Therapeutics?
The latest impact factor listed by LetPub is 1.3; CiteScore 2.3, h-index 67.
How long does peer review take at Journal of Cancer Research and Therapeutics?
Based on the dates recorded on 81 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 165 days (interquartile range 103–262 days); authors report an average review time of about 6 months; the community-reported acceptance is “about 95%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Journal of Cancer Research and Therapeutics in?
The journal's website gives JCR Q4; by category, ONCOLOGY Q4 (287/333). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Journal of Cancer Research and Therapeutics?
According to LetPub and DOAJ records, Journal of Cancer Research and Therapeutics is indexed in SCIE and Scopus.
Is Journal of Cancer Research and Therapeutics open access, and what is the APC?
Journal of Cancer Research and Therapeutics is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .